Hormone replacement therapy and cardioprotection: A new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women

Journal of Cardiovascular Medicine

Volumn 10, Issue 1, 2009, Pages 85-92

  Rosano, Giuseppe M C ^a   Maffei, Silvia ^b   Andreassi, Maria G ^b   Vitale, Cristiana ^a   Vassalle, Cristina ^b   Gambacciani, Marco ^a,e   Stramba Badiale, Marco ^c   Mercuro, Giuseppe ^d  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Cardiovascular; Estrogen; Hormone replacement therapy; Prognosis; Women

Indexed keywords

CONJUGATED ESTROGEN; DROSPIRENONE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE;

AGING; CANCER RISK; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HEART PROTECTION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; ITALY; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OBSERVATIONAL STUDY; OVARY; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; SOCIETY; THERAPY EFFECT; TIME;

AGE FACTORS; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HEART DISEASES; HUMANS; ITALY; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; WOMEN'S HEALTH;

EID: 67650908094     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328313e979     Document Type: Review

References (70)

1. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27:994-1005.
2. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105-1110.
3. Rosano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. Cardiol Rev 2002; 10:51-60.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47-63.
5. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38:199-210.
6. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115:954-963.
7. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989; 117:1209-1214.
8. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775.
9. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151:75-78.
10. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102-1109.
11. The writing group for the PEPI trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273:199-208.
12. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70:289-293.
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
14. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized controlled Trial. JAMA 2004; 291:1701-1712.
15. Rosano GM, Patrizi R, Leonardo F, Ponikowski P, Collins P, Sarrel PM, Chierchia SL. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. Am J Cardiol 1997; 80:815-817.
16. Mercuro G,PoddaA,PitzalisL, Zoncu S, MasciaM,Melis GB, Rosano GM. Evidence of a role of endogenous estrogen in the modulation of autonomic nervous system. Am J Cardiol 2000; 85:787-789.
17. Gambacciani M, Ciapponi M, Cappagli B, Canussi B, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999; 2:37-44.
18. Rosano GM, Vitale C, Silvestri A, Fini M. The metabolic syndrome in women: implications for therapy. Int J Clin Pract Suppl 2004; 20-25.
19. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005; 258:250-256.
20. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
21. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002; 347:716-725.
22. De Aloysio D, Gambacciani M, Meschia M, Pansini F, Modena AB, Bolis PF, et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 1999; 147:147-153.
23. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992; 8(Suppl 1):99-103.
24. Staessen JA, Celis H, Fagard R. The epidemiology of the association between hypertension and menopause. J Hum Hypertens 1998; 12:587-592.
25. Hu G, DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003; 46:608-617.
26. Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Response to surgical menopause, salt sensitivity, and NO bioavailability in women. Hypertension 2006; 47:1168-1174.
27. Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams R. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003; 91:1421-1426.
28. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613.
29. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477.
30. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al., WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356:2591-2602.
31. Pansini F, Bacchi Modena AB, de Aloysio D, Gambacciani M, Meschia M, Parazzini F, et al., ICARUS Study Group. Sociodemographic and clinical factors associated with HRT use in women attending menopause clinics in Italy. Climacteric 2000; 3:241-247.
32. Gambacciani M, Rosano GM, Monteleone P, Fini M, Genazzani AR. Clinical relevance of the HERS trial. Lancet 2002; 360:641.
33. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53:605-719.
34. Oparil S. Hormones and vasoprotection. Hypertension 1999; 33:170-176.
35. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman AW, Sussman MS, Ouyang P, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43:985-991.
36. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994; 89:1501-1510.
37. Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? Int J Cardiol 2003; 87:1-8.
38. Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E, et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 2005; 12:552-558.
39. Rosano GM, Collins P, Gerbara O, Sheiban I, Silvestri A, Wajngarten M, et al. Effect of estradiol 17beta upon coronary artery vasoconstrictor response to methylergometrine maleate in female menopausal patients. Int J Cardiol 2006; 107:254-259.
40. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, et al. 17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92:24-30.
41. Herrington DM, Espeland MA, Crouse JR 3rd, Robertson J, Riley WA, McBurnie MA, Burke GL. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001; 21:1955-1961.
42. Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JJ, Michler RE, et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res 2000; 46:172-179.
43. Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta 2007; 1772:72-80.
44. Nakamura Y, Suzuki T, Miki Y, Tazawa C, Senzaki K, Moriya T, et al. Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol 2004; 219:17-26.
45. Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007; 49:1358-1363.
46. Mompeo B, Tscheuschilsuren G, Aust G, Metz S, Spanel-Borowski K. Estrogen receptor expression and synthesis in the human internal thoracic artery. Ann Anat 2003; 185:57-65.
47. Vitale C, Mercuro G, Cerquetani E, Marazzi G, Patrizi R, Pelliccia F, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol 2008; 28:348-352.
48. Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E, et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 2005; 12:552-558.
49. Vitale C, Gebara O, Mercuro G, Wajngarten M, Silvestri A, Rossini P, et al. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk. Maturitas 2005; 50:239-246.
50. Meendering JR, Torgrimson BN, Miller NP, Kaplan PF, Minson CT. Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. Am J Physiol Heart Circ Physiol 2008; 294:H1630-H1637.
51. Sherwood A, Bower JK, McFetridge-Durdle J, Blumenthal JA, Newby LK, Hinderliter AL. Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol 2007; 27:1782-1787.
52. Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007; 153:439-444.
53. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6:632-637.
54. Voke J, Keidan J, Pavord S, Spencer NH, Hunt BJ, British Society for Haematology Obstetric Haematology Group. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007; 139:545-558.
55. Blanco-Molina A, Trujillo-Santos J, Criado J, Lopez L, Lecumberri R, Gutierrez R, Monreal M, RIETE Investigators. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97:186-190.
56. Canonico M, Oger E, Conard J, Meyer G, Lé vesque H, Trillot N, et al., Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4:1259-1265.
57. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al., Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112:3495-3500.
58. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al., Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-845.
59. Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002; 15:816-822.
60. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112:1979-1984.
61. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48:246-253.
62. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007; 28:2028-2040.
63. Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information on Drugs. 2nd ed. Geneva, Switzerland: CIOMS; 1998.
64. Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008; 11:108-123.
65. Hannaford P, Elliott A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2005; 71:95-98.
66. Elliott AM, Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2006; 73:331-335.
67. Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, Alkhaddo J, et al. Hormone replacement therapy as a risk factor for nonsmall cell lung cancer: results of a case-control study. Oncology 2007; 73:305-310.
68. Mahabir S, Spitz MR, Barrera SL, Dong YQ, Eastham C, Forman MR. Dietary boron and hormone replacement therapy as risk factors for lung cancer in women. Am J Epidemiol 2008; 167:1070-1080.
69. Rodriguez C, Spencer Feigelson H, Deka A, Patel AV, Jacobs EJ, Thun MJ, Calle EE. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2008; 17:655-660.
70. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.